Angiotech receives European approval for Quill(R) SRS wound closure product
17 Mai 2007 - 3:00PM
PR Newswire (US)
New Class of Wound Closure Product Expected to Launch in Europe
Mid-Year VANCOUVER, May 17 /PRNewswire-FirstCall/ -- Angiotech
Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), a global
specialty pharmaceutical and medical device company today announced
that is has received European approval for CE mark of its Quill(R)
Self-Retaining System (SRS). Launched early in the year in the
United States, Quill(R) SRS is expected to launch commercially in
Europe mid-year. "With the potential to improve patient outcomes,
save time in the operating room, and enhance procedural techniques,
Quill(R) SRS represents the next generation in wound closure
technology," said Dr. William Hunter, President and Chief Executive
Officer of Angiotech. "In the first three months of launch in the
United States we have seen strong physician interest in this
product, and expect similar reception in Europe," added Dr. Hunter.
"We believe that Quill(R) has a unique advantage as its patented
self-retaining system (SRS) allows for wound closure without the
need for knots," commented Dr. Santi Corsaro, Vice President, Sales
and Marketing in Europe. "With the approval of Quill(R) SRS in
Europe, as well as the expected approval of the Vascular Wrap(TM)
product later this year, we are starting to build our sales and
marketing infrastructure to support these two important
franchises," added Dr. Corsaro. About the Quill(R) Self-Retaining
System (SRS) The innovative Quill(R) SRS represents the next
generation of wound closure technology. A patented helical barbed
design enables surgeons to suture without the use of knots. The
absence of knots provides a wide range of clinical and economic
benefits, including: Potential to improve patient outcomes: -
Minimizes complications associated with knots - Potential to
improve wound healing - May enhance cosmesis Potential to save time
in the operating room: - Achieves potentially significant time
savings, especially in suture intensive procedures Enhanced
procedural techniques: - Allows closure of difficult wounds -
Enables suturing in tight laces - Allows the surgeon to control
tension Note on Forward Looking Statements: Statements contained in
this press release that are not based on historical fact, including
without limitation statements containing the words "believes,"
"may," "plans," "will," "estimate," "continue," "anticipates,"
"intends," "expects" and similar expressions, constitute
"forward-looking statements" within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and constitute
"forward-looking information" within the meaning of applicable
Canadian securities laws. All such statements are made pursuant to
the "safe harbor" provisions of applicable securities legislation.
Forward-looking statements in this release include but are not
limited to statements regarding; financial benefits to Angiotech
that could potentially be realized from Angiotech's wound closure
business, the ability of Angiotech to commercialize the Quill(R)
SRS product and to develop and commercialize any successive product
lines, that a substantial market exists for the product, that the
product will perform as expected, that the product represents an
improvement over current wound closure methods and that these
improvements could be beneficial to physicians and to patients.
Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
events or developments to be materially different from any future
results, events or developments expressed or implied by such
forward-looking statements. Many such risks, uncertainties and
other factors are taken into account as part of our assumptions
underlying these forward-looking statements and include, among
others, the following; general economic and business conditions,
both nationally and in the regions in which we operate; market
demand; technological changes that could impact our existing
products or our ability to develop and commercialize future
products; competition; existing governmental regulations and
changes in, or the failure to comply with, governmental
regulations; decisions, and the timing of decisions, made by health
regulatory agencies regarding approval of our technology and
products; the requirement for substantial funding to conduct
research and development and to expand commercialization
activities; and any other factors that may affect performance. In
addition, our business is subject to certain operating risks that
may cause the actual results expressed or implied by the
forward-looking statements in this report to differ materially from
our actual results. These operating risks include; poor performance
of the product in the clinical setting; adverse events related to
the use of the product; improper estimation of the size of the
wound closure market; adverse results or unexpected delays in
clinical development processes; our ability to attract and retain
qualified personnel; our ability to successfully complete
preclinical and clinical development of our products; changes in
business strategy or development plans; our failure to obtain
patent protection for discoveries; loss of patent protection
resulting from third party challenges to our patents;
commercialization limitations imposed by patents owned or
controlled by third parties; our ability to obtain rights to
technology from licensors; liability for patent claims and other
claims asserted against us; our ability to obtain and enforce
timely patent and other intellectual property protection for our
technology and products; the ability to enter into, and to
maintain, corporate alliances relating to the development and
commercialization of our technology and products; market acceptance
of our technology and products; our ability to successfully
manufacture, market and sell our products; the continued
availability of capital to finance our activities; our ability to
continue to integrate into our business the operations of American
Medical Instruments Holdings, Inc. and our ability to achieve the
operational and other synergies and the other commercial or
financial benefits expected as a result of that acquisition; and
any other factors referenced in our annual information form and
other filings with the applicable Canadian securities regulatory
authorities or the SEC. Given these uncertainties, assumptions and
risk factors, readers are cautioned not to place undue reliance on
such forward-looking statements. We disclaim any obligation to
update any such factors or to publicly announce the result of any
revisions to any of the forward-looking statements contained in
this prospectus to reflect future results, events or developments.
(R) A registered trademark of Quill Medical, Inc., a wholly-owned
subsidiary of Angiotech Pharmaceuticals, Inc. (TM) A trademark of
Angiotech Pharmaceuticals, Inc. About Angiotech Angiotech
Pharmaceuticals, Inc. is a global specialty pharmaceutical and
medical device company with over 1,500 dedicated employees.
Angiotech discovers, develops and markets innovative treatment
solutions for diseases or complications associated with medical
device implants, surgical interventions and acute injury. To find
out more about Angiotech (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please
visit our website at http://www.angiotech.com/. CONTACT: Janet
Craig VP, Investor Relations and Corporate Communications,
Angiotech Pharmaceuticals, Inc., (604) 221-6933, ; Jodi Regts,
Manager, Investor Relations and Corporate Communications, Angiotech
Pharmaceuticals, Inc., (604) 221-7930, DATASOURCE: Angiotech
Pharmaceuticals, Inc. CONTACT: Janet Craig VP, Investor Relations
and Corporate Communications, Angiotech Pharmaceuticals, Inc.,
(604) 221-6933, ; Jodi Regts, Manager, Investor Relations and
Corporate Communications, Angiotech Pharmaceuticals, Inc., (604)
221-7930,
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024